Standout Papers

The molecular biology of chronic myeloid leukemia 2000 2026 2008 2017 1.2k
  1. The molecular biology of chronic myeloid leukemia (2000)
    Michael W. Deininger, John M. Goldman et al. Blood
  2. The development of imatinib as a therapeutic agent for chronic myeloid leukemia (2004)
    Michael W. Deininger, Elisabeth Buchdunger et al. Blood
  3. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet (2009)
    Michele Baccarani, Jörge E. Cortes et al. Journal of Clinical Oncology
  4. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants (2005)
    Thomas O’Hare, Denise K. Walters et al. Cancer Research
  5. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017)
    Andreas Hochhaus, Richard A. Larson et al. New England Journal of Medicine
  6. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance (2000)
    François Xavier Mahon, Michael W. Deininger et al. Blood
  7. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (2010)
    Amie S. Corbin, Anupriya Agarwal et al. Journal of Clinical Investigation
  8. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine
  9. The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells (1997)
    Michael W. Deininger, John M. Goldman et al. Blood
  10. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML (2013)
    Julia E. Maxson, Jason Gotlib et al. New England Journal of Medicine
  11. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology
  12. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia (2015)
    Javid J. Moslehi, Michael W. Deininger Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 13 from Science/Nature 94 standout
Sub-graph 1 of 16

Citing Papers

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
2023 Standout
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
1 intermediate paper

Works of Michael W. Deininger being referenced

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
2005 Standout
The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells
1997 Standout

Author Peers

Author Last Decade Papers Cites
Michael W. Deininger 15874 12145 7397 397 20.6k
François Guilhot 14255 10326 6618 347 18.0k
Giuseppe Saglio 18032 13149 6880 643 24.4k
Jerald P. Radich 16407 9835 5356 393 21.5k
Carlo Gambacorti‐Passerini 7750 5384 3247 342 13.4k
Oliver G. Ottmann 10174 4907 2719 369 15.8k
Gautam Borthakur 12840 6396 2324 799 17.1k
Francisco Cervantes 14240 15506 7023 321 19.5k
Deborah A. Thomas 12009 10024 2589 448 22.7k
Junia V. Melo 7131 5468 3166 119 10.0k
Animesh Pardanani 12806 14938 7870 463 21.1k

All Works

Loading papers...

Rankless by CCL
2026